Phase 3 — approaching approval
- Retatrutide (Eli Lilly) — Triple agonist for obesity, T2D, MASH, OSA
- CagriSema (Novo Nordisk) — Amylin (cagrilintide) + semaglutide combination
- Orforglipron (Eli Lilly) — Oral non-peptide GLP-1
- Survodutide (Boehringer/Zealand) — GLP-1/glucagon dual
- Mazdutide (Innovent/Lilly) — GLP-1/glucagon dual (China focus)
Phase 2
- Multiple PYY analogs from various pharma
- Bimagrumab (ActRIIB blocker, myostatin pathway) — restarted programs
- Klotho-derived peptides for longevity
- Mitochondrial peptides (humanin analogs, MOTS-c analogs)
Phase 1
- Multiple AI-designed peptide candidates entering trials
- Klotho peptide analogs
- New GH secretagogues with improved selectivity
When is the next major peptide approval expected?
Retatrutide late 2026 or 2027; multiple oral GLP-1s in 2027-2028.